Subcutaneous apomorphine in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1989-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.52.4.544PMID 2738604PMCID PMC1032319
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Subcutaneous apomorphine in Parkinson's disease

  1989cited by this paper
• Subcutaneous apomorphine in Parkinson's disease.

  1988cited by this paper
• Subcutaneous apomorphine in parkinsonian on-off oscillations.

  1988cited by this paper
• Apomorphine infusion for motor fluctuations in Parkinson's disease.

  1987cited by this paper
• Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.

  1979cited by this paper
• Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

  1976cited by this paper
• The Lungs in Ankylosing Spondylitis

  1971cited by this paper
• Apomorphine in Parkinsonian tremor.

  1970cited by this paper

• Apomorphine: past, present and future in Parkinson's disease and beyond.

  2025cites this paper
• Influence of continuous subcutaneous apomorphine infusion on cognition and behavior in Parkinson's disease: A systematic review.

  2024cites this paper
• Dopamine agonists in the treatment of Parkinson's disease: the show must go on

  2024cites this paper
• Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

  2023cites this paper
• Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection

  2023cites this paper
• L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin

  2023cites this paper
• Motor and non-motor effects of apomorphine infusion

  2022cites this paper
• European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

  2022cites this paper
• European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies

  2022cites this paper
• Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience

  2022cites this paper
• Pharmacotherapy of Psychosis in Parkinson’s Disease

  2020cites this paper
• The next chapter in symptomatic Parkinson disease treatments.

  2019cites this paper
• Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance

  2018cites this paper
• Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

  2017cites this paper
• Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.

  2017cites this paper
• [Practical use of continuous apomorphine infusion via pump].

  2017cites this paper
• Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.

  2017cites this paper
• Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue clinique [Apomorphine subcutaneous continuous infusion in Parkinson's disease: The clinical point of view]

  2016cites this paper
• Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue pharmacologique

  2016cites this paper
• Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.

  2016cites this paper
• Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.

  2016cites this paper
• Morning akinesia in Parkinson's disease: challenges and solutions

  2016cites this paper
• The efficacy of apomorphine - A non-motor perspective.

  2016cites this paper
• Die kontinuierliche subkutane Apomorphingabe

  2015cites this paper
• Role of Apomorphine in the Treatment of Parkinson’s Disease

  2015cites this paper
• Advanced stages of PD: interventional therapies and related patient-centered care

  2015cites this paper
• Apomorphine hydrochloride for the treatment of Parkinson’s disease

  2015cites this paper
• Wann sind Pfl aster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?

  2014cites this paper
• Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?

  2014cites this paper
• The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms

  2014cites this paper
• Apomorfina w zaawansowanej chorobie Parkinsona

  2013cites this paper
• Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease

  2013cites this paper
• Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.

  2013cites this paper
• Determinants of Aggregation Resistance in Human Antibody VH Domains

  2013cites this paper
• Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease.

  2013cites this paper
• Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

  2011cites this paper
• Subthalamic Deep Brain Stimulation for Parkinson's Disease

  2011cites this paper
• Kontinuierliche Therapie mit der Apomorphinpumpe

  2011cites this paper
• Apomorphin zur subkutanen Dauerinfusion bei fortgeschrittenem Morbus Parkinson: Effektivität, Verträglichkeit und Patientenzufriedenheit im Langzeitverlauf

  2011cites this paper
• Apomorphine pharmacokinetics in Parkinsonism after intranasal and subcutaneous application

  2010cites this paper
• Die Zukunft der invasiven Parkinson-Therapie

  2010cites this paper
• Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

  2009cites this paper
• Subthalamic Nucleus Stimulation for Parkinson's Disease

  2009cites this paper
• Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

  2008cites this paper
• [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].

  2008cites this paper
• Structural basis for ligand-binding and activation of D1-like dopamine receptors

  2008cites this paper
• Apomorphine in the treatment of Parkinson's disease

  2007cites this paper
• What the future holds for deep brain stimulation

  2007cites this paper
• [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].

  2006cites this paper
• Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease

  2006cites this paper
• L’apomorphine en perfusion sous-cutanée continue dans le traitement de la maladie de Parkinson

  2006cites this paper
• Other pharmacological treatments for motor complications and dyskinesias

  2005cites this paper
• The neuropsychology and functional anatomy of timing

  2005cites this paper
• Subkutane Dauerinfusion mit Apomorphin

  2005cites this paper
• Subkutane Applikation von Apomorphin - Pharmakologische Eigenschaften und alternative Applikationswege

  2005cites this paper
• A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.

  2005cites this paper
• Literature review

  2004cites this paper
• Other formulations and future considerations for apomorphine for subcutaneous injection therapy

  2004cites this paper
• Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease

  2004cites this paper
• Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson’s disease

  2004cites this paper
• Practical considerations in the use of apomorphine injectable

  2004cites this paper
• Subcutaneously administered apomorphine

  2004cites this paper
• Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

  2004cites this paper
• Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.

  2004cites this paper
• An evidence-based review of Dopamine receptor agonists in the treatment of Parkinson`s disease.

  2002cites this paper
• Intracortical inhibition is reduced in a patient with a lesion in the posterolateral thalamus

  2002cites this paper
• Riluzole therapy in cervical dystonia

  2002cites this paper
• Postural asymmetries following unilateral subthalomotomy for advanced Parkinson's disease

  2002cites this paper
• Improvement of severe trunk spasms by bilateral high‐frequency stimulation of the motor thalamus in a patient with chorea‐acanthocytosis

  2002cites this paper
• X‐linked dystonia (“Lubag”) presenting predominantly with parkinsonism: A more benign phenotype?

  2002cites this paper
• Objective tinnitus associated with essential laryngeal myoclonus: Report of two cases

  2002cites this paper
• Late‐onset axial jerky dystonia due to the DYT1 deletion

  2002cites this paper
• Life‐threatening parkinsonism induced by kava‐kava

  2002cites this paper
• Levodopa‐induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two‐year, prospective follow‐up

  2002cites this paper
• Focal pathological startle following pontine infarction

  2002cites this paper
• Levodopa‐induced ocular dyskinesias in Parkinson's disease

  2002cites this paper
• Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

  2001cites this paper
• In vitro and in vivo long term release of apomorphine from polymer matrices.

  2000cites this paper
• Effects of apomorphine on visual functions in Parkinson's disease

  2000cites this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson’s Disease

  1999cites this paper
• Management of Parkinson's Disease: A Review of Current and New Therapies

  1999cites this paper
• Parenterale Therapie mit Dopaminagonisten

  1999cites this paper
• Transient increase of pancreatic enzymes evoked by apomorphine in Parkinson's disease

  1998influential citation
• Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease

  1998cites this paper
• Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up

  1998cites this paper
• A double‐blind, placebo‐controlled study of intranasal apomorphine spray as a rescue agent for off‐states in Parkinson's disease

  1998cites this paper
• Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.

  1997cites this paper
• Microencapsulation of apomorphine HCI with gelatin

  1997cites this paper
• lontophoretic Delivery of Apomorphine II: An In Vivo Study in Patients with Parkinson's Disease

  1997cites this paper
• Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance

  1995cites this paper
• Apomorphine for Motor Fluctuations and Freezing in Parkinson's Disease

  1995cites this paper
• Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment

  1995cites this paper
• Apomorphine in patients with Parkinson's disease.

  1995cites this paper
• Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study.

  1995cites this paper
• Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?

  1995cites this paper
• Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?

  1994cites this paper
• Intrastriatal infusion of lisuride--a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats.

  1994cites this paper
• Population Pharmacokinetics of Apomorphine in Patients with Parkinson’s Disease

  1994cites this paper
• Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.

  1993cites this paper
• Apomorphine test for dopaminergic responsiveness: A dose assessment study

  1993cites this paper